<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344277</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0238</org_study_id>
    <nct_id>NCT02344277</nct_id>
  </id_info>
  <brief_title>Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients</brief_title>
  <acronym>S-ICD Brugada</acronym>
  <official_title>Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brugada syndrome is an inherited arrhythmia syndrome with an increased risk of syncope and
      sudden death resulting from episodes of polymorphic ventricular tachychardia and
      fibrillation. Currently, there is no medical therapy for the Brugada syndrome and the only
      treatment available is the implantation of an ICD. There is no discussion on the interest of
      the ICD implantation in secondary prevention and in patients who experienced syncope but the
      best therapeutic is more difficult to draw in asymptomatic patients. Recently we demonstrated
      that in asymptomatic patients with a spontaneous type 1 aspect of Brugada syndrome, (i) there
      was a significant risk of ventricular arrhythmia, (ii) the problem of inappropriate shocks
      can be solve with a good ICD programming and (iii) the problem of lead failure remains the
      main problem in this young population very active and represent the main limitation to larger
      indication of ICD implantation in this population with a very long life expectancy as these
      patients had a normal life expectancy except the risk of ventricular arrhythmia.

      In this context the S-ICD System (Boston Scientific Inc.) which is an implantable
      defibrillator technology that treats ventricular tachyarrhythmias using a subcutaneous pulse
      generator and electrode system rather than a transvenous lead system, represents a very
      attractive opportunity as it gives the possibility to protect the patients of the risk of
      ventricular arrhythmia with no risk of lead failure. However, as this is a new technology and
      as Brugada syndrome patients are a very specific population (very active patients, specific
      and changing over time ECG aspect that is at risk of T wave over sensing and high risk of
      SVT), it seems important to evaluate the effectiveness and the safety of S-ICD in this
      specific context.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>appropriate number of shocks to the number of shocks recorded at 5 years after S-ICD implantation</measure>
    <time_frame>5 years</time_frame>
    <description>The primary endpoint is the rate of successful appropriate shocks recorded at 5 years after S-ICD implantation in Brugada syndrome patients. In this population that will be a mix of symptomatic and asymptomatic patients, we anticipate a 1.5% per year event rate that will allow us to have a total of 15 patients receiving an appropriate shock at the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>annual rate of inappropriate shocks</measure>
    <time_frame>5 years</time_frame>
    <description>The secondary end point will be the annual rate of inappropriate shocks, the complications of S-ICD implantation and the complications during the follow-up.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Brugada Syndrome</condition>
  <condition>S-ICD System (Implantable Defibrillator)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>S-ICD System (implantable defibrillator)</intervention_name>
    <description>The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.
Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects selected for participation will be symptomatic or asymptomatic Brugada
        patients and, implanted or not with any ICD. Site investigators are responsible for
        screening. Subjects must meet all inclusion criteria. Subjects with any exclusion criteria
        will be excluded. The recruitment of the patients will be performed in a selected number of
        centers specifically involved in the management of patients affected by the Brugada
        syndrome in Europe and in which databases of patients are available.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patient with type I Brugada syndrome eligible for implantation of an S-ICD system:

        Symptomatic : (history of resuscitated sudden death, syncope) with an ECG showing an aspect
        of Brugada syndrome type I before or after pharmacological tests (ajmaline or flecainide
        test) according to the criteria of the consensus conference and after ECG validation by the
        Clinical Events Committee experts.

        Asymptomatic: with an aspect of spontaneous type I Brugada syndrome after ECG validation by
        the Clinical Events Committee experts.

          -  Brugada syndrome patient with Indication for ICD replacement.

          -  No contra-indication for S-ICD implantation (anatomic or physiologic criteria) with
             particular attention to the validation of the ECG prescreening implantation. For this
             study at least 2 vectors must be suitable for S-ICD implantation.

          -  Patients whose age is 18 years or above, or of legal age to give informed consent
             specific to state and national law.

          -  Patients who are willing and capable of providing informed consent, participating in
             all testing associated with this clinical investigation at an approved clinical
             investigational center.

        Exclusion Criteria:

          -  Incessant ventricular tachycardia (VT) and/or documented spontaneous, frequently
             recurring VT that is reliably terminated with anti-tachycardia pacing.

          -  Patients with unipolar pacemakers or implanted devices that revert to unipolar pacing.

          -  Presence of any severe medical condition such that the patient is not expected to
             survive for the planned study follow-up period.

          -  Minor, patient under trusteeship or under guardianship.

          -  Patients who currently participate in an investigational drug or device that
             clinically interferes with the S-ICD-Brugada registry study endpoints and results.

          -  Female of childbearing potential without adequate contraception at the time of the
             implantation.

          -  Inability to comply with the follow-up schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent PROBST, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent PROBST, Pr</last_name>
    <phone>02.40.16.56.99</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aur√©lie THOLLET, INGENEER</last_name>
    <phone>02.40.16.52.79</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Tfelt - Hansen, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jacob Tfelt-Hansen, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Vinther, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Michael Vinther, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fr√©d√©ric SACHER, Pr</last_name>
      <phone>05.57.65.64.71</phone>
    </contact>
    <investigator>
      <last_name>Fr√©d√©ric SACHER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MANSOURATI, Pr</last_name>
      <phone>02.98.34.73.91</phone>
    </contact>
    <investigator>
      <last_name>Jacques MANSOURATI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal DEFAYE, PU-PH</last_name>
      <phone>04.76.76.54.37</phone>
    </contact>
    <investigator>
      <last_name>Pascal DEFAYE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salem Kacet, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Salem Kacet, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe CHEVALIER, Pr</last_name>
      <phone>04.72.35.70.27</phone>
    </contact>
    <investigator>
      <last_name>Philippe CHEVALIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude DEHARO, Pr</last_name>
      <phone>04.91.38.65.75</phone>
    </contact>
    <investigator>
      <last_name>Jean-Claude DEHARO, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pasqui√© Jean-Luc, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Pasqui√© Jean-Luc, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugues BLANGY, Pr</last_name>
      <phone>03.83.25.81.75</phone>
    </contact>
    <investigator>
      <last_name>Hugues BLANGY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent PROBST, Pr</last_name>
      <phone>02.40.16.56.99</phone>
    </contact>
    <investigator>
      <last_name>Vincent PROBST, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP H√¥pital BIch√¢t</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine LEENHARDT, Pr</last_name>
      <phone>01.40.25.77.92</phone>
    </contact>
    <investigator>
      <last_name>Antoine LEENHARDT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris University Hospital - La piti√©-Salp√©tri√®re</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Badenco, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Badenco, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MABO, Pr</last_name>
      <phone>02.99.28.25.25</phone>
    </contact>
    <investigator>
      <last_name>Philippe MABO, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La R√©union University Hospital</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ga√´l CLERICI, Dr</last_name>
      <phone>+262 2 62 35 91 53</phone>
    </contact>
    <investigator>
      <last_name>Ga√´l CLERICI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence JESEL-MOREL, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Laurence JESEL-MOREL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe MAURY, Dr</last_name>
      <phone>05.61.32.30.54</phone>
    </contact>
    <investigator>
      <last_name>Jean-Philippe MAURY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique BABUTY, Pr</last_name>
      <phone>02.47.47.46.50</phone>
    </contact>
    <investigator>
      <last_name>Dominique BABUTY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68 167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin BORGGREFE, Pr</last_name>
      <phone>+49 621 383 3024</phone>
    </contact>
    <investigator>
      <last_name>Martin BORGGREFE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fiorenzo Gaita, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Fiorenzo Gaita, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep BRUGADA TERRADELLAS, Pr</last_name>
      <phone>+34 932 275 733</phone>
    </contact>
    <investigator>
      <last_name>Josep BRUGADA TERRADELLAS, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernandez Lozano Ignacio, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Fernandez Lozano Ignacio, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneaous Implantable Cardiac Defibrillator</keyword>
  <keyword>Brugada syndrome</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

